Prognos Health
Headquarters
New York, NYFounded
2010CEO / Founder
Bill FebboEmployees
51-200Funding
Series D+ — $140MProducts
1 product listedAvg. AI Score
6.9/10Website
prognos.ai/
Profile updated
About Prognos Health
Prognos Health operates a healthcare data and artificial intelligence platform focused on clinical diagnostics. The company was originally founded in 2010 (under the name Predictive Health, later rebranded to Prognos), and is headquartered in New York, NY. It aggregates and analyzes laboratory test results and other clinical data to identify disease patterns earlier in the care continuum.
The company's platform is used by pharmaceutical companies, life sciences organizations, and healthcare payers to support clinical development, patient identification, and disease progression modeling. Prognos maintains a large registry of de-identified clinical diagnostic and lab data, drawing from laboratory networks and electronic health record sources across the United States, and applies machine learning models to detect early indicators of conditions such as chronic kidney disease, cancer, and autoimmune disorders.
Prognos Health has raised capital across multiple funding rounds from investors including Merck Global Health Innovation Fund, Safeguard Scientifics, and other healthcare-focused venture investors. The company has grown through data partnerships with diagnostic laboratories and health systems to expand the scale of its clinical data registry.
Specialties
Financials
Dated, source-cited figures. Estimates are marked.
Products by Prognos Health
All products by Prognos Health reviewed by our AI panel of experts.
Clinical data analytics for healthcare and life sciences
How Our Review Panel Scores Prognos Health
Six independent reviewer personalities assessed Prognos Health's product on their own terms. They disagreed by 2.0 points — The Power User was the hardest to convince, The Domain Strategist the most positive.
Averaged across 1 reviewed product in our catalog. Scores are out of 10.
Competitive Landscape
Who Prognos Health competes with, and how they differ.
Komodo's Healthcare Map aggregates de-identified claims and EHR data across roughly 330 million patients for life-sciences targeting and market-access analytics, competing directly with Prognos's lab-data-centric real-world-data marketplace for pharma and payers.
1 product reviewed on TopReviewedHealthVerity runs a similar de-identified data marketplace connecting claims, EHR and lab data for life-sciences customers, competing head-to-head with Prognos on real-world-data licensing and analytics.
Flatiron built its real-world-data business on oncology EHR records sourced from cancer clinics and licenses that data to pharma for trial design and regulatory submissions, versus Prognos's broader base of clinical lab results spanning 30-plus disease areas.
1 product reviewed on TopReviewed
Tempus generates its real-world data mainly from genomic sequencing and molecular testing performed in its own labs and sells it alongside diagnostics to pharma, while Prognos aggregates third-party clinical lab results without running its own testing operations.
1 product reviewed on TopReviewed
Innovaccer's Health Cloud unifies EHR, claims and lab data mainly for health systems and payers running value-based-care programs, whereas Prognos sells its lab-based real-world data primarily to pharma and life-sciences customers.
1 product reviewed on TopReviewedCompany Timeline
Key milestones in Prognos Health's history, with sources.
- Partnership
Strategic Collaboration With BioReference Health on Precision Medicine
BioReference Health, an OPKO Health lab company, partnered with Prognos to combine genomic and real-world lab data, targeting precision medicine and drug-development research for the pharmaceutical industry.
biospace.com - Funding
Growth Equity Round — $23M Co-Led by Marshall Wace and Safeguard Scientifics
Prognos raised $23 million in growth equity co-led by Marshall Wace and Safeguard Scientifics, with Cigna Ventures, Hikma Ventures, Hunt Holdings, Labcorp, Maywic, Merck Global Health Innovation Fund and Red and Blue Ventures also participating.
prognoshealth.com - Funding
Funding Round — $20.5M From Cigna, Hikma, Merck GHI Fund and Safeguard Scientifics
Prognos (formerly Medivo) raised $20.5 million from Cigna, Guardian Life Insurance, Hermed, Hikma Pharmaceuticals, Maywic, Merck Global Health Innovation Fund and Safeguard Scientifics, bringing total funding to $42 million.
mobihealthnews.com - Milestone
Medivo Renamed Prognos, Pivots From Patients to Payers and Pharma
Healthcare data analytics company Medivo renamed itself Prognos, pivoting from patient-facing lab-result access to selling AI-driven disease-prediction analytics built on its lab database to payers and pharmaceutical companies.
healthcareitnews.com - Acquisition
Medivo Acquires OnTrack Diabetes App
Medivo acquired OnTrack Diabetes, an Android diabetes-management app downloaded 500,000 times, for an undisclosed amount — its second consumer app acquisition after WellApps.
mobihealthnews.com - Funding
Series B — $15M Led by Merck Global Health Innovation Fund
Medivo raised $15 million in a second funding round led by new investor Merck Global Health Innovation Fund, with Safeguard Scientifics and MentorTech Ventures also participating, bringing total funding to $22 million.
mobihealthnews.com - Acquisition
Medivo Acquires WellApps
Medivo acquired WellApps, maker of the GI Monitor app for tracking inflammatory bowel disease and Crohn's disease, and folded it into the Medivo Monitor and PatientPath platforms.
siliconindia.com - Funding
Series A — $7M Led by Safeguard Scientifics
Safeguard Scientifics led a $7 million Series A financing round for New York health-IT startup Medivo, which combined diagnostic lab testing with healthcare IT.
massdevice.com
Explore AI Software Reviews
Browse multi-perspective AI panel reviews across hundreds of AI tools, agents, and platforms. Find the right software with insights from all six expert seats — Decision Maker, Domain Strategist, Finance Lead, Domain Practitioner, Power User, and Skeptic.